Independent study: CARB-X-supported antibiotic projects are five times more likely to reach clinical trials
Summary
An independent, peer-reviewed study published in Health Affairs Scholar found that CARB-X, a global push incentive for antimicrobial resistance (AMR), significantly accelerates the development of life-saving antibiotics. Projects supported by CARB-X have nearly five times greater odds of advancing to clinical trials compared to non-supported projects. This is the first-ever independent evaluation of a push incentive to address AMR, validating CARB-X's mission to combat antibiotic-resistant bacteria by de-risking early-stage R&D.
Source
bskyIndependent study: CARB-X-supported antibiotic projects are five times more likely to reach clinical trialscarb-x.orgKey quotes
· 3 pulledFirst-of-its-kind, peer-reviewed evaluation demonstrates CARB-X delivers on its mission to accelerate life-saving innovation
Research and development projects supported by CARB-X have nearly five times greater odds to advance in clinical trials
Published in Health Affairs Scholar, the new study found that CARB-X-supported projects are significantly more likely to progress
You might also wanna read
University of Pennsylvania researchers develop AI tool to accelerate antibiotic development
Researchers at the University of Pennsylvania have developed an AI tool designed to accelerate antibiotic development by enhancing the antib
nih.gov·11d ago
Japan's bold experiment to curb antibiotic misuse has been a huge success. Could it work in the US?
Stewardship / Resistance Scan for Apr 02, 2020
WHO Report: Antibiotic Resistance Growing Faster Than Expected, Causing 1.2 Million Annual Deaths
A new WHO report reveals that antibiotic resistance is growing at an alarming rate, with antimicrobial resistance already responsible for ap
npr.org·8mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.